أعرض في EDS

Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes

التفاصيل البيبلوغرافية
العنوان: Pharmacogenomic landscape of COVID-19 therapies from Indian population genomes
المؤلفون: Anjali Bajaj, S Sreedevi, Shantaraman Kalyanaraman, Devarshi U. Gajjar, Kavita Pandhare, Nachimuthu Senthil Kumar, J Ezhil Ramya, Nikhil V. Palande, Sumit Sharma, Mohamed Imran, Rohit Yadav, Vigneshwar Senthivel, Mohit Mangla, Mohit Kumar Divakar, Sridhar Sivasubbu, Ranjan Jyoti Sarma, Lalchhandama Chhakchhuak, S. Jain, Disha Sharma, Ronibala Soraisham, Prashant Kumar Mishra, Sudip Kumar Sahana, Raskin Erusan Rajagopal, Mercy Rophina, Rahul C. Bhoyar, Anushree Mishra, Yumnam Silla Devi, Arun G. Jadhao, Sanjay Siwach, Aayush Gupta, B K Binukumar, Mitali Mukerji, Andrew Vanlallawma, Ganga Nath Jha, Nishat Ashrafi, A K Vidhya, Abhinav Jain, Samatha Mathew, Kandarp Joshi, Meya Kumla, Sivaprakash Ramalingam, Debasis Dash, Ambily Sivadas, Vishu Gupta, Sangam Goswami, Radha Mahadevan, Pabitha Devi, Vinod Scaria, Arushi Batra, Sunitha Kandasamy, P Nirmala Devi, Savinitha Prakash, Bani Jolly
المصدر: Pharmacogenomics
سنة النشر: 2021
مصطلحات موضوعية: 0301 basic medicine, Drug, Indian population, Coronavirus disease 2019 (COVID-19), Genotype, Pharmacogenomic Variants, media_common.quotation_subject, India, Ethnic populations, Bioinformatics, drug–drug–gene interactions, Genome, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Asian People, Genetics, Medicine, Humans, In patient, Drug Interactions, media_common, Pharmacology, pharmacogenomics, business.industry, SARS-CoV-2, COVID-19, Pharmacogenomic Testing, COVID-19 Drug Treatment, 030104 developmental biology, Pharmacogenetics, 030220 oncology & carcinogenesis, Pharmacogenomics, Molecular Medicine, COVID-19 therapies, drug–drug interactions, business, Research Article
الوصف: Aim: Numerous drugs are being widely prescribed for COVID-19 treatment without any direct evidence for the drug safety/efficacy in patients across diverse ethnic populations. Materials & methods: We analyzed whole genomes of 1029 Indian individuals (IndiGen) to understand the extent of drug–gene (pharmacogenetic), drug–drug and drug–drug–gene interactions associated with COVID-19 therapy in the Indian population. Results: We identified 30 clinically significant pharmacogenetic variants and 73 predicted deleterious pharmacogenetic variants. COVID-19-associated pharmacogenes were substantially overlapped with those of metabolic disorder therapeutics. CYP3A4, ABCB1 and ALB are the most shared pharmacogenes. Fifteen COVID-19 therapeutics were predicted as likely drug–drug interaction candidates when used with four CYP inhibitor drugs. Conclusion: Our findings provide actionable insights for future validation studies and improved clinical decisions for COVID-19 therapy in Indians.
تدمد: 1744-8042
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac653b698b9224222cb99b6d7569df86
https://pubmed.ncbi.nlm.nih.gov/34142560
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....ac653b698b9224222cb99b6d7569df86
قاعدة البيانات: OpenAIRE
الوصف
تدمد:17448042